ClinicalTrials.gg
RecruitingNCT07949526TIGHTUpdated Nov 19, 2026

Compressive Dressing and Pharyngocutaneous Fistula After Primary Total Laryngectomy

An observational study in Laryngeal Neoplasms, Squamous Cell Carcinoma of the Larynx and Pharyngocutaneous Fistula, sponsored by IRCCS San Raffaele. Recruiting at 26 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by IRCCS San Raffaele · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
950
Ages
18 Years and older
Sex
All
01

Study summary

Pharyngocutaneous fistula (PCF) is one of the most feared complications after total laryngectomy. A compressive neck dressing is often applied after surgery to try to prevent it, but there is no consensus on whether it works or how long it should be kept, and practice varies widely between centers. This multicenter, retrospective, observational study compares the rate of PCF in adult patients with laryngeal squamous cell carcinoma who underwent primary total laryngectomy with direct closure of the hypopharyngeal mucosa and who did or did not receive a postoperative compressive dressing. It also examines whether the duration of the dressing affects the risk of fistula and how fistulas were managed in the two groups. All data are collected from existing medical records; no additional treatment or examination is performed.

Read the detailed description

PCF occurs in about 14% of primary total laryngectomies and about 28% of salvage procedures. It is associated with prolonged hospital stay, higher costs, delayed adjuvant treatment, and further complications. No study has directly compared patients managed with and without a postoperative compressive dressing.

This is a non-profit, multicenter, national, retrospective observational study coordinated by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Consecutive patients who underwent primary total laryngectomy from January 1, 2014 to the study start date are included. All patients were treated according to routine clinical practice at each center. Patients are divided into two groups according to postoperative management: compressive dressing of the cervical region over the neopharyngeal suture (Group A) or no compressive dressing (Group B).

Data are extracted from medical records and entered in pseudonymized form in an electronic case report form (REDCap). Collected variables include demographics, smoking and alcohol use, comorbidities, preoperative laboratory values and inflammatory indices, tumor site and clinical stage, surgical details (neck dissection, thyroidectomy, pharyngeal closure technique, salivary stent, primary voice prosthesis), postoperative antibiotic protocol, time to oral feeding, and fistula characteristics and management.

The planned sample size is 950 patients (475 per group), which provides 80% power to detect a 6.0% difference in fistula rate between groups, assuming a baseline rate of 14.3% in the group without compressive dressing, using a two-sided Fisher's exact test with alpha 0.05. The primary outcome will be analyzed with Fisher's exact test. Secondary outcomes will be analyzed with logistic and linear regression. Confounding will be addressed with propensity score matching, inverse probability weighting, or covariate adjustment, as appropriate.

02

Conditions studied

  • Laryngeal Neoplasms
  • Squamous Cell Carcinoma of the Larynx
  • Pharyngocutaneous Fistula

Keywords

  • total laryngectomy
  • pharyngocutaneous fistula
  • compressive dressing
  • postoperative complications
03

In context

Laryngeal Neoplasms

257 studies on the registry are indexed under Laryngeal Neoplasms; 68 are open to participants now.

This study's planned enrollment of 950 is above the median of 100 across 60 observational studies indexed under Laryngeal Neoplasms.

Browse Laryngeal Neoplasms studies →

Lead sponsor

IRCCS San Raffaele is the lead sponsor of 456 studies on the registry; 236 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Consecutive adult patients with squamous cell carcinoma of the larynx who underwent primary total laryngectomy with direct closure of the hypopharyngeal mucosa at the participating Italian otolaryngology centers from January 1, 2014 to the study start date.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Squamous cell carcinoma of the larynx treated with primary total laryngectomy
  • Primary closure of the hypopharyngeal mucosa
  • Age 18 years or older
  • to study participation and to personal data processing
  • Availability of data on comorbidities, laboratory parameters, and postoperative management

Exclusion criteria

Exclusion Criteria:

  • Salvage total laryngectomy
  • Previous radiotherapy or chemoradiotherapy to the head and neck
  • Previous open surgery of the pharyngolaryngeal region
  • Reconstruction with a free or pedicled flap (inlay or onlay)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
950 participants (estimated)
Patient registry
No

Groups and cohorts

  • Compressive dressing (Group A)

    Patients who received a postoperative compressive dressing of the cervical region over the neopharyngeal suture after primary total laryngectomy, according to routine clinical practice at the treating center.

    Other: Compressive neck dressing

  • No compressive dressing (Group B)

    Patients who did not receive a postoperative compressive dressing after primary total laryngectomy, according to routine clinical practice at the treating center.

Interventions

  • OtherCompressive neck dressing

    Postoperative compressive dressing applied to the cervical region over the neopharyngeal suture. This is an exposure observed in routine clinical practice; it is not assigned by the study.

06

What researchers measure

Primary outcomes

  1. Incidence of pharyngocutaneous fistula

    Number and percentage of patients who develop a pharyngocutaneous fistula in each group (compressive dressing vs no compressive dressing).

    Time frame: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Secondary outcomes

  1. Incidence of pharyngocutaneous fistula by duration of compressive dressing

    Number and percentage of patients in Group A who develop a pharyngocutaneous fistula, stratified by duration of the compressive dressing (days).

    Time frame: During the postoperative hospital stay (from surgery to discharge), up to 60 days

  2. Time to onset of pharyngocutaneous fistula

    Number of days from surgery to diagnosis of pharyngocutaneous fistula in each group.

    Time frame: During the postoperative hospital stay (from surgery to discharge), up to 60 days

  3. Type of management of pharyngocutaneous fistula

    Number and percentage of patients with fistula managed conservatively (compressive dressing) or surgically in each group.

    Time frame: During the postoperative hospital stay (from surgery to discharge), up to 60 days

  4. Resolution of pharyngocutaneous fistula

    Number and percentage of patients whose fistula resolved, by initial group and type of management.

    Time frame: During the postoperative hospital stay (from surgery to discharge), up to 60 days

  5. Time to resolution of pharyngocutaneous fistula

    Number of days from diagnosis to resolution of the fistula, by initial group and type of management.

    Time frame: During the postoperative hospital stay (from surgery to discharge), up to 60 days

07

Study locations

26 of 26 sites recruiting
08

References and documents

Publications

  • Sayles M, Grant DG. Preventing pharyngo-cutaneous fistula in total laryngectomy: a systematic review and meta-analysis. Laryngoscope. 2014 May;124(5):1150-63. doi: 10.1002/lary.24448. Epub 2013 Nov 15. PubMed 24122657 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the published results will be made available upon reasonable request to the Principal Investigator.

Time frame: After publication of the study results in a peer-reviewed journal.

Access criteria: Data will be shared with researchers who submit a motivated request to the Principal Investigator of the coordinating center (IRCCS Azienda Ospedaliero-Universitaria di Bologna).

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Jan 2027, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 19, 2026
StartActual
May 5, 2025
Primary completionEst.
Jan 5, 2027
CompletionEst.
Mar 31, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949526
Lead sponsor
IRCCS San Raffaele
Responsible party
Andrea Galli (MD, Otorhinolaryngologist, Researcher, IRCCS San Raffaele) — Principal investigator
First posted
Nov 19, 2026
Start date
May 5, 2025
Primary completion
Jan 5, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Edoardo Serafini, MD, Medical Degree
Contact
edoardo.serafini3@unibo.it
+39 051 2145263
Edoardo Serafini, Medical Degree
principal investigator · IRCCS Azienda Ospedaliero-Universitaria di Bologna

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion